Novel Brentuximab Vedotin Combination Therapies Show Promising Activity in Highly Refractory CD30+ Non-Hodgkin Lymphoma: A Case Series and Review of the Literature

Figure 3

Staging NM-PET imaging after chemotherapy. (a) PET staging after 2 cycles of R-CHOP: partial anatomic response to therapy. Interval decrease in diffuse lymphadenopathy in comparison to initial CT. (b) Staging PET-CT after 5 cycles of R-CHOP, 1 cycle of R-DHAP, and IT methotrexate and cytarabine treatments. Widespread diffuse adenopathy with overall progression. (c) Staging after 2 cycles of brentuximab and topotecan. Significant decreases in size and metabolic activity of the diffuse adenopathy were observed.

(a)

(b)

(c)